Navigation Links
FDA Approves New surgery Treatment for Farsightedness

The US Food and Drug Administration has approved a new treatment for farsightedness known as conductive keratoplasty. The technique uses radiofrequency energy to// shrink small areas of the cornea, the transparent coat on the surface of the eyeball. Unlike laser in situ keratomileusis (LASIK), in which the surface of the eye is reshaped using a laser, conductive keratoplasty does not require cutting or tissue removal.

The treatment may become the preferred method of correcting farsightedness in older patients. Conductive keratoplasty is very comfortable and convenient, especially for older patients who don't want something as invasive or as complex as LASIK. It is also helpful for older patients who might have dry eye or surface epithelial irregularities, which could be exacerbated by LASIK.

The average age of patients who undergo LASIK is in the early 40s, while for conductive keratoplasty, the average age for patients has been 58. LASIK is approved for higher degrees of farsightedness and astigmatism, which is blurry vision usually caused by an uneven curvature of the cornea. Conductive keratoplasty could also be safer for patients with glaucoma, because keratoplasty does not require the temporary elevation of pressure within the eye that is induced during LASIK.

The procedure is normally conducted with topical anesthesia. Afterwards, patients normally experience some eye irritation, which resolves within 24 to 48 hours. Most of the patients have been followed for 2 years, and they have expressed overwhelming satisfaction with the procedure.
'"/>




Page: 1

Related medicine news :

1. FDA Approves Contraceptive Ring
2. FDA Approves New HIV Drug, Viread
3. FDA Approves Birth Control Skin Patch
4. FDA Approves New Arthritis Drug, Bextra
5. FDA Approves Elidel Cream for Eczema
6. FDA Approves New Anti-Clotting Drug
7. FDA Approves Anti-Cancer Cell Drug - Zevalin
8. FDA Approves Remodulin for Pulmonary Hypertension
9. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
10. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
11. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
Post Your Comments:
(Date:10/10/2008)...ewswire/ -- Do you think that the blind,can,t use ...nd the October,17 open house at the Virginia Rehab..., and see how instructors there empower the blind ...ng lives through non-visual,techniques taught at t...nue, is holding an open house to,celebrate the gra...
(Date:10/10/2008)...RNewswire/ -- NuView Life Sciences Inc.,(NuView) h...ces Inc.,(Trace), including operations of the line... in Denton, Texas. The Trace facility produces,Cop...llium-201 used in,molecular imaging and nuclear me...d that "We are confident that by improving operati...
(Date:10/10/2008)...artly to blame , , FRIDAY, Oct. 10 (Heal...s who have diabetes, being depressed was associate...dy. , Publishing in the October issue of the ...s from the University of Washington tracked 10,704...) who had diabetes and were enrolled in a disease ...
(Date:10/10/2008)... (NIH) scientists have identified a protein that p...od cells, T and B cells, enabling them to interact...ting immunity after an infection. Their finding m...netic defect that prevents them from making this p... a common virus that otherwise is rarely fatal (Ep...
Breaking Medicine News(10 mins):Health News:Virginia Rehabilitation Center for the Blind and Vision Impaired Celebrates Opening of New Student Dormitory 2Health News:Older Diabetics With Depression Face Higher Death Rate 2Health News:NIH scientists discover crucial control in long-lasting immunity 2Health News:NIH scientists discover crucial control in long-lasting immunity 3
...to a new study, patients with lung disease suffere...nhaled steroids. Researchers in Texas studied a gr...nary disease (COPD).// All received a high dose of...r a period of four months. After this time, they e...
...to a report, giving radiation to surgical treatmen...n the survival of patients. But the findings sugge...ery may help// improve the patient's quality of li...rrence at or near the original tumor site in the r...
...as invented and man learnt how to cook food. At fi...ety and a change from raw food, but today it domin...ste buds do appreciate raw food. Whether just to m...s or at home as a filler,no meal is complete witho...
...s in a study observed that human cytomegalovirus c...r. Although some people have a genetic predisposit...or no obvious reason.// Researchers at the Univers...link between viral infection and colon cancer. Fi...
Other Medicine News:Health News:Keep fit with salads 2Health News:Keep fit with salads 3
(Date:10/9/2008)...ted in November 2008, BOTHELL, Wash., Oct. 9 /PRN...DD ) announced today the completion of patient enr...tal trials to evaluate the safety and,efficacy of ...buprofen for,the over-the-counter (OTC) market. Th...this pivotal trial in November 2008. Ibuprofen is ...
(Date:10/8/2008)...wire-USNewswire/ -- The facts are,overwhelming. Ev...sub-Saharan Africa. More than 35,000,000 women, ch... died of AIDS. The Foundation for Hospices,in Sub-...their families,find compassion and relief from suf...nering initiative links African hospices and palli...
(Date:10/8/2008)...s Research That May Offer New Hope to,Heart Failur...nally, over 3,000 people are,waiting for a heart t...alf,of those will receive a transplant. Now, pione... paving the way for how to treat congestive heart,...ews Release, go to:, http://www.prnewswire.com/mnr...
(Date:10/8/2008)...e TAXUS(R) Element(TM) Platinum Chromium ... 8 /- Boston Scientific,Cor... completed enrollment in,the PERSEUS trial, design...S(R) Element(TM) paclitaxel-eluting coronary stent... 1,500 patients at 100 U.S. and,international cent...
Breaking Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 1Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 2Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 3Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 4Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 5Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 6Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 7Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 8Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 9Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 10Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 11Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 12Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 13Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 14Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 15Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 16Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 17Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 18Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 19Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 20Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 21Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 22Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 23Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 24Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 25Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 26Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 27Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 28Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 29Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 30Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 31Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 32Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 33Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 34Sanofi aventis Announces a Good Third Quarter Performance 3B Increase in 2007 full year earnings growth guidance 5103 35Varian Inc Offers New Products for the Rapid Purification of Synthetic Oligonucleotides 5098 1Varian Inc Offers New Products for the Rapid Purification of Synthetic Oligonucleotides 5098 2Childrens gardens mushrooming 1053 1Childrens gardens mushrooming 1053 2Caesarean births pose higher risks for mother and baby 5096 1Caesarean births pose higher risks for mother and baby 5096 2
... July 3, 2007-- – The appearance of a,rash i... is,strongly associated with longer survival, acco...er, OSI Pharmaceuticals, Inc. This is,not the firs...al,advantage with EGFR inhibitors – a class ...tumumab and others designed to,block overproductio...
... July 3, 2007-- Ongoing therapeutic cancer vaccine...ring a,patient’s immune system to shrink tum...trials tend to live longer and respond,better to s...al,Cancer Research, a journal of the American Asso...ncer Institute researchers asks a,fundamental ques...
Other Medicine Technology:Skin Rash Actually Signifies Better Outcomes for Pancreatic and,Lung Cancer Patients 2Skin Rash Actually Signifies Better Outcomes for Pancreatic and,Lung Cancer Patients 3Skin Rash Actually Signifies Better Outcomes for Pancreatic and,Lung Cancer Patients 4From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 2From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 3
Triad Plus Skin Protectant Swabsticks prepare the skin for maximum adhesion of a dressing or bandage. When dry, they leave a thin film on the skin's surface. This provides a clean surface and a barri
BD Persist Plus protective barrier provides a one-step antimicrobial barrier with minimum of 1% chlorhexidine with Up to 7-day antimicrobial effectiveness.
BETADINE® Solution Swabsticks are indicated whenever a topical microbicide is applied most conveniently with a swabstick.
BD Persist contains 70% alcohol and 10% povidone iodine formulated in a unique polymer base, forming a barrier on the skin. The barrier creates a protective environment for the povidone iodin
Medicine Products: